Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: The RECOMB study

HIV Medicine

Volumn 14, Issue 6, 2013, Pages 327-336

  Ribera, E ^a   Larrousse, M ^b   Curran, A ^a   Negredo, E ^c   Clotet, B ^c   Estrada, V ^d   Sanz, J ^e   Berenguer, J ^f   Rubio, R ^g   Pulido, F ^g   Ferrer, P ^h   Alvarez, Ml ^h   Arterburn, S ⁱ   Martinez E ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Gilead Sciences   (Spain)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

Adverse effects; HIV; Lipoatrophy; Switch; Tenofovir emtricitabine; Zidovudine lamivudine

Indexed keywords

ANTILIPEMIC AGENT; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FAT MASS; FEMALE; FOLLOW UP; GASTROINTESINAL INTOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; LACTIC ACIDOSIS; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NEPHROLITHIASIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADENINE; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878940913     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12011     Document Type: Article

References (33)

1. Palella FJ, Jr, Delaney KM, Moorman AC etal. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 38: 853-860.
2. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17: 169-177.
3. Duran S, Saves M, Spire B etal. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441-2444.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
5. Carr A, Samaras K, Burton S etal. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
6. Martinez E, Larrousse M, Podzamczer D, Gatell JM. Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophy. HIV Med 2009; 10: 257-261.
7. Podzamczer D, Ferrer E, Martinez E etal. How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses 2009; 25: 563-567.
8. Josse G, Gensanne D, Aquilina C etal. Human immunodeficiency virus atropy induces modification of subcutaneous adipose tissue architecture: in vivo visualization by high-resolution magnetic resonance imaging. Br J Dermatol 2009; 160: 741-746.
9. Bacchetti P, Gripshover B, Grunfeld C etal. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-131.
10. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
11. Tavassoli N, Bagheri H, Sommet A etal. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Pharmacotherapy 2006; 26: 154-161.
12. Gallant JE, DeJesus E, Arribas JR etal. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
13. Martin A, Smith DE, Carr A etal. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-1036.
14. McComsey GA, Ward DJ, Hessenthaler SM etal. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
15. European AIDS Clinical Society (EACS). Guidelines, Version 6.1, 2012. Available at www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.1-English-Nov2012.pdf (accessed 12 December 2012).
16. John M, McKinnon EJ, James IR etal. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29-33.
17. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
18. Podzamczer D, Ferrer E, Sanchez P etal. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139-147.
19. Tsekes G, Chrysos G, Douskas G etal. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 2002; 3: 85-90.
20. Spanish AIDS Society. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualización enero 2012. Available at www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verimprimir.pdf (accessed 12 December 2012).
21. Arribas JR, Pozniak AL, Gallant JE etal. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78.
22. Knobel H, Alonso J, Casado JL etal. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16: 605-613.
23. Carr A, Workman C, Smith DE etal. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-215.
24. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-28.
25. Moyle GJ, Sabin CA, Cartledge J etal. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.
26. Ribera E, Paradiñeiro JC, Curran A etal. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). HIV Clin Trials 2008; 9: 407-417.
27. Fisher M, Moyle GJ, Shahmanesh M etal. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51: 562-568.
28. Martinez E, Arranz JA, Podzamczer D etal. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51: 290-297.
29. DeJesus E, Ruane P, McDonald C etal. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008; 9: 103-114.
30. DeJesus E, Young B, Morales-Ramirez JO etal. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009; 51: 163-174.
31. Tungsiripat M, O'Riordan MA, Storer N etal. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials 2009; 10: 314-319.
32. Benn P, Sauret-Jackson V, Cartledge J etal. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Med 2009; 10: 351-355.
33. Yang Y, Yap M, Oo TN, Paton NI. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy. HIV Clin Trials 2008; 9: 399-406.